Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Linoleic Acid
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Linoleic Acid

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A doubly unsaturated fatty acid, occurring widely in plant glycosides.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (914 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed)

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: 9,12-Octadecadienoic Acid; 9,12 Octadecadienoic Acid; Acid, 9,12-Octadecadienoic; Linoleate; Linoleic Acid, Calcium Salt, (Z,Z)-Isomer; Linoleic Acid, (Z,E)-Isomer; Linoelaidic Acid, (E,Z)-Isomer; Linoleic Acid, (Z,Z)-Isomer, 14C-Labeled.

Where it fits in the MeSH classification

Broader topics
Linoleic Acids

Research landscape

PubMed indexes 7,309 records tagged with the MeSH heading “Linoleic Acid” (counts retrieved 2026-10-31). 1,039 of them (14.2%) were published from 2020 onward, and the busiest period so far is through 1999 with 2,616 records.

Reviews account for 363 records (5.0%) and meta-analyses for 35. Randomized controlled trials number 246 (3.4%) as a share of all records on the topic.

PubMed records by publication periodthrough 1999: 2,616 records; 2000-2009: 1,976 records; 2010-2019: 1,678 records; 2020 onward: 1,039 records2,616through 19991,9762000-20091,6782010-20191,0392020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19992,616
2000-20091,976
2010-20191,678
2020 onward1,039
Share of records by publication typeReviews: 5.0 percent; Meta-analyses: 0.5 percent; Randomized controlled trials: 3.4 percentReviews5.0% (363)Meta-analyses0.5% (35)Randomized controlled trials3.4% (246)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 7,309 PubMed records
TypeRecordsShare
Reviews3635.0%
Meta-analyses350.5%
Randomized controlled trials2463.4%

Method: PubMed query "Linoleic Acid"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein
Toelzer C, Gupta K, Yadav SKN, Borucu U, Davidson AD, Kavanagh Williamson M, et al.
2020Research article
Design not recorded in structured metadata
392cc by
PMID 32958580 · DOI · PMC8050947
Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction
Lu X, Yu H, Ma Q, Shen S, Das UN
2010Research article
Design not recorded in structured metadata
112cc by
PMID 20868498 · DOI · PMC2954911
Linoleic Acid: A Narrative Review of the Effects of Increased Intake in the Standard American Diet and Associations with Chronic Disease
Mercola J, D'Adamo CR
2023Review article
Design not recorded in structured metadata
99cc by
PMID 37513547 · DOI · PMC10386285
Synergistic treatment of linoleic acid and cefazolin on Staphylococcus aureus biofilm-related catheter infections
Ham S, Kim H-S, Jo MJ, Cha E, Ryoo H-S, Kim H, et al.
2025Research article
Design not recorded in structured metadata
2cc by
PMID 40396720 · DOI · PMC12175515

Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein [1]

Research article Toelzer C, Gupta K, Yadav SKN, Borucu U, Davidson AD, Kavanagh Williamson M, et al. · · 2020 · cited 392 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a global crisis.
Closing excerpt
Our structure directly links LA and S, setting the stage for intervention strategies that target LA binding by SARS-CoV-2.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (142 words)

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a global crisis. Key to SARS-CoV-2 therapeutic development is unraveling the mechanisms that drive high infectivity, broad tissue tropism, and severe pathology. Our 2.85-angstrom cryo-electron microscopy structure of SARS-CoV-2 spike (S) glycoprotein reveals that the receptor binding domains tightly bind the essential free fatty acid linoleic acid (LA) in three composite binding pockets. A similar pocket also appears to be present in the highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). LA binding stabilizes a locked S conformation, resulting in reduced angiotensin-converting enzyme 2 (ACE2) interaction in vitro. In human cells, LA supplementation synergizes with the COVID-19 drug remdesivir, suppressing SARS-CoV-2 replication. Our structure directly links LA and S, setting the stage for intervention strategies that target LA binding by SARS-CoV-2.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32958580 · DOI · PMC8050947

Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction [2]

Research article Lu X, Yu H, Ma Q, Shen S, Das UN · · 2010 · cited 112 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Some polyunsaturated fatty acids (PUFAs), if not all, have been shown to have tumoricidal action, but their exact mechanism(s) of action is not clear.
Closing excerpt
Thus, LA induced cancer cell apoptosis by enhancing cellular oxidant status and inducing mitochondrial dysfunction.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (220 words)

Some polyunsaturated fatty acids (PUFAs), if not all, have been shown to have tumoricidal action, but their exact mechanism(s) of action is not clear. In the present study, we observed that n-6 PUFA linoleic acid (LA) inhibited tumor cell growth at high concentrations (above 300 μM); while low concentrations (100-200 μM) promoted proliferation. Analysis of cell mitochondrial membrane potential, reactive oxygen species (ROS) formation, malondialdehyde (MDA) accumulation and superoxide dismutase (SOD) activity suggested that anti-cancer action of LA is due to enhanced ROS generation and decreased cell anti-oxidant capacity that resulted in mitochondrial damage. Of the three cell lines tested, semi-differentiated colorectal cancer cells RKO were most sensitive to the cytotoxic action of LA, followed by undifferentiated colorectal cancer cell line (LOVO) while the normal human umbilical vein endothelial cells (HUVEC) were the most resistant (the degree of sensitivity to LA is as follows: RKO > LOVO > HUVEC). LA induced cell death was primed by mitochondrial apoptotic pathway. Pre-incubation of cancer cells with 100 μM LA for 24 hr enhanced sensitivity of differentiated and semi-differentiated cells to the subsequent exposure to LA. The relative resistance of LOVO cells to the cytotoxic action of LA is due to a reduction in the activation of caspase-3. Thus, LA induced cancer cell apoptosis by enhancing cellular oxidant status and inducing mitochondrial dysfunction.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 20868498 · DOI · PMC2954911

Linoleic Acid: A Narrative Review of the Effects of Increased Intake in the Standard American Diet and Associations with Chronic Disease [3]

Review article Mercola J, D'Adamo CR · · 2023 · cited 99 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The intake of linoleic acid (LA) has increased dramatically in the standard American diet.
Closing excerpt
Therefore, additional research-evaluating approaches to reduce OXLAM formation and cardiolipin derangements following LA consumption are warranted.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (255 words)

The intake of linoleic acid (LA) has increased dramatically in the standard American diet. LA is generally promoted as supporting human health, but there exists controversy regarding whether the amount of LA currently consumed in the standard American diet supports human health. The goal of this narrative review is to explore the mechanisms that underlie the hypothesis that excessive LA intake may harm human health. While LA is considered to be an essential fatty acid and support health when consumed in modest amounts, an excessive intake of LA leads to the formation of oxidized linoleic acid metabolites (OXLAMs), impairments in mitochondrial function through suboptimal cardiolipin composition, and likely contributes to many chronic diseases that became an epidemic in the 20th century, and whose prevalence continues to increase. The standard American diet comprises 14 to 25 times more omega-6 fatty acids than omega-3 fatty acids, with the majority of omega-6 intake coming from LA. As LA consumption increases, the potential for OXLAM formation also increases. OXLAMs have been associated with various illnesses, including cardiovascular disease, cancer, and Alzheimer's disease, among others. Lowering dietary LA intake can help reduce the production and accumulation of OXLAMs implicated in chronic diseases. While there are other problematic components in the standard American diet, the half-life of LA is approximately two years, which means the damage can be far more persistent than other dietary factors, and the impact of reducing excessive LA intake takes time. Therefore, additional research-evaluating approaches to reduce OXLAM formation and cardiolipin derangements following LA consumption are warranted.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37513547 · DOI · PMC10386285

Synergistic treatment of linoleic acid and cefazolin on Staphylococcus aureus biofilm-related catheter infections [4]

Research article Ham S, Kim H-S, Jo MJ, Cha E, Ryoo H-S, Kim H, et al. · · 2025 · cited 2 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Staphylococcus aureus is a human pathogen that causes severe infections through biofilm formation.
Closing excerpt
aureus biofilms, especially in peritoneal dialysis.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (297 words)

Staphylococcus aureus is a human pathogen that causes severe infections through biofilm formation. S. aureus biofilm is particularly susceptible to catheters in patients undergoing peritoneal dialysis. Although antibiotics are used to treat catheter infections, high-concentration treatments adversely affect human host immune systems and change the physicochemical properties of the catheters. To improve therapeutic outcomes without side effects, we combined antibiotics and natural products. In this study, we propose a combination of linoleic acid (LA) and cefazolin (CFZ) to treat S. aureus infections synergistically and apply it to catheter environments and in vivo systems. LA is a polyunsaturated fatty acid derived from natural products, and CFZ is a major antibiotic used to treat S. aureus catheter-related infections. The optimum synergistic condition was determined using silicon pad-forming biofilm similar to catheter materials. S. aureus biofilms were considerably inhibited in vitro and in vivo owing to the improved antibacterial effects. Furthermore, the combination negatively regulated the chemokine levels in the peritoneum, kidney, and liver extracted from mouse models. Moreover, it did not affect the cytotoxicity of human omentum mesothelial cells and the functions of the kidney and liver. Therefore, the combination of LA and CFZ could be a potential synergistic therapy for S. aureus catheter infections.IMPORTANCECatheter contamination is commonly caused by Staphylococcus aureus biofilm formation, primarily in peritoneal dialysis patients. Although antibiotics are used to treat catheter infections, high concentrations of antibiotics impair the immune system of the human host and alter the physicochemical properties of catheters. Therefore, it is crucial to improve therapeutic outcomes while minimizing the side effects of antibiotics. Combined treatments with natural products can be solutions to alleviate these problems. Our study offers a new synergistic combination (linoleic acid and cefazolin) for the control of catheter infections caused by S. aureus biofilms, especially in peritoneal dialysis.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40396720 · DOI · PMC12175515

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action [5]
    Belury MA · Annu Rev Nutr · 2002 · cited 451 times (Europe PMC)
  • Research article Dietary linoleic acid and risk of coronary heart disease: a systematic review and meta-analysis of prospective cohort studies [6]
    Farvid MS, Ding M, Pan A, Sun Q, Chiuve SE, Steffen LM, et al. · Circulation · 2014 · cited 390 times (Europe PMC)
  • Research article Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis [7]
    Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, et al. · BMJ · 2013 · cited 342 times (Europe PMC)
  • Research article Modifying milk fat composition of dairy cows to enhance fatty acids beneficial to human health [8]
    Lock AL, Bauman DE · Lipids · 2004 · cited 322 times (Europe PMC)
  • Research article Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality [9]
    Marklund M, Wu JHY, Imamura F, Del Gobbo LC, Fretts A, de Goede J, et al. · Circulation · 2019 · cited 284 times (Europe PMC)
  • Research article Linoleic acid [10]
    Whelan J, Fritsche K · Adv Nutr · 2013 · cited 253 times (Europe PMC)

References

  1. Toelzer C, Gupta K, Yadav SKN, Borucu U, Davidson AD, Kavanagh Williamson M, et al.. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. . 2020. PMID 32958580 · DOI · PMC8050947
  2. Lu X, Yu H, Ma Q, Shen S, Das UN. Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction. . 2010. PMID 20868498 · DOI · PMC2954911
  3. Mercola J, D'Adamo CR. Linoleic Acid: A Narrative Review of the Effects of Increased Intake in the Standard American Diet and Associations with Chronic Disease. . 2023. PMID 37513547 · DOI · PMC10386285
  4. Ham S, Kim H-S, Jo MJ, Cha E, Ryoo H-S, Kim H, et al.. Synergistic treatment of linoleic acid and cefazolin on Staphylococcus aureus biofilm-related catheter infections. . 2025. PMID 40396720 · DOI · PMC12175515
  5. Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr. 2002. PMID 12055356 · DOI
  6. Farvid MS, Ding M, Pan A, Sun Q, Chiuve SE, Steffen LM, et al.. Dietary linoleic acid and risk of coronary heart disease: a systematic review and meta-analysis of prospective cohort studies. Circulation. 2014. PMID 25161045 · DOI · PMC4334131
  7. Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, et al.. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013. PMID 23386268 · DOI · PMC4688426
  8. Lock AL, Bauman DE. Modifying milk fat composition of dairy cows to enhance fatty acids beneficial to human health. Lipids. 2004. PMID 15736916 · DOI
  9. Marklund M, Wu JHY, Imamura F, Del Gobbo LC, Fretts A, de Goede J, et al.. Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality. Circulation. 2019. PMID 30971107 · DOI · PMC6582360
  10. Whelan J, Fritsche K. Linoleic acid. Adv Nutr. 2013. PMID 23674797 · DOI · PMC3650500

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • alpha-Linolenic AcidDrugs and Chemicals
  • Arachidonic AcidDrugs and Chemicals
  • Trans Fatty AcidsDrugs and Chemicals
  • IsoprostanesDrugs and Chemicals
  • Oleic AcidDrugs and Chemicals
  • Eicosapentaenoic AcidDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

7,309
PubMed records on this heading
14%
published since 2020
363
review articles
246
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • alpha-Linolenic AcidDrugs and Chemicals
  • Arachidonic AcidDrugs and Chemicals
  • Trans Fatty AcidsDrugs and Chemicals
  • IsoprostanesDrugs and Chemicals
  • Oleic AcidDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support